Search

Your search keyword '"Jang, Eun Jin"' showing total 519 results
Start Over Author "Jang, Eun Jin"
519 results on '"Jang, Eun Jin"'

61. Gcap14 is a microtubule plus-end-tracking protein coordinating microtubule–actin crosstalk during neurodevelopment

Author

Mun, Dong Jin, primary, Goo, Bon Seong, additional, Suh, Bo Kyoung, additional, Hong, Ji-Ho, additional, Woo, Youngsik, additional, Kim, Soo Jeong, additional, Kim, Seunghyun, additional, Lee, Su Been, additional, Won, Yubin, additional, Yoo, Jin Yeong, additional, Cho, Eunbyul, additional, Jang, Eun Jin, additional, Nhung, Truong Thi My, additional, Triet, Hong Minh, additional, An, Hongyul, additional, Lee, Haeryun, additional, Nguyen, Minh Dang, additional, Park, Seung-Yeol, additional, Baek, Seung Tae, additional, and Park, Sang Ki, additional

Published
2023
Full Text
View/download PDF

64. Mapping health assessment questionnaire disability index (HAQ-DI) score, pain visual analog scale (VAS), and disease activity score in 28 joints (DAS28) onto the EuroQol-5D (EQ-5D) utility score with the KORean Observational study Network for Arthritis (KORONA) registry data

Author

Kim, Hye-Lin, Kim, Dam, Jang, Eun Jin, Lee, Min-Young, Song, Hyun Jin, Park, Sun-Young, Cho, Soo-Kyung, Sung, Yoon-Kyoung, Choi, Chan-Bum, Won, Soyoung, Bang, So-Young, Cha, Hoon-Suk, Choe, Jung-Yoon, Chung, Won Tae, Hong, Seung-Jae, Jun, Jae-Bum, Kim, Jinseok, Kim, Seong-Kyu, Kim, Tae-Hwan, Kim, Tae-Jong, Koh, Eunmi, Lee, Hwajeong, Lee, Hye-Soon, Lee, Jisoo, Lee, Shin-Seok, Lee, Sung Won, Park, Sung-Hoon, Shim, Seung-Cheol, Yoo, Dae-Hyun, Yoon, Bo Young, Bae, Sang-Cheol, and Lee, Eui-Kyung

Published
2016
Full Text
View/download PDF

71. Comparisons of exacerbations and mortality among regular inhaled therapies for patients with stable chronic obstructive pulmonary disease: Systematic review and Bayesian network meta-analysis

Author

Lee, Hyun Woo, Park, Jimyung, Jo, Junwoo, Jang, Eun Jin, and Lee, Chang-Hoon

Subjects
EPUB (Standard), Patient outcomes, Mortality, Tiotropium, Indacaterol, Chronic obstructive lung disease -- Patient outcomes, Medical research, Pharmaceutical industry, Vilanterol, Lung diseases, Pneumonia, Respiratory tract diseases, Respiratory system agents, Drugs, Corticosteroid drugs
Abstract

Author(s): Hyun Woo Lee 1, Jimyung Park 1, Junwoo Jo 2, Eun Jin Jang 3, Chang-Hoon Lee 1,* Introduction Inhaled drugs, including long-acting muscarinic antagonists (LAMAs), long-acting beta-agonists (LABAs), inhaled [...], Background Although exacerbation and mortality are the most important clinical outcomes of stable chronic obstructive pulmonary disease (COPD), the drug classes that are the most efficacious in reducing exacerbation and mortality among all possible inhaled drugs have not been determined. Methods and findings We performed a systematic review (SR) and Bayesian network meta-analysis (NMA). We searched Medline, EMBASE, the Cochrane Central Register of Controlled Trials, ClinicalTrials.gov, the European Union Clinical Trials Register, and the official websites of pharmaceutical companies (from inception to July 9, 2019). The eligibility criteria were as follows: (1) parallel-design randomized controlled trials (RCTs); (2) adults with stable COPD; (3) comparisons among long-acting muscarinic antagonists (LAMAs), long-acting beta-agonists (LABAs), inhaled corticosteroids (ICSs), combined treatment (ICS/LAMA/LABA, LAMA/LABA, or ICS/LABA), or a placebo; and (4) study duration [greater than or equal to] 12 weeks. This study was prospectively registered in International Prospective Register of Systematic Reviews (PROSPERO; CRD42017069087). In total, 219 trials involving 228,710 patients were included. Compared with placebo, all drug classes significantly reduced the total exacerbations and moderate to severe exacerbations. ICS/LAMA/LABA was the most efficacious treatment for reducing the exacerbation risk (odds ratio [OR] = 0.57; 95% credible interval [CrI] 0.50-0.64; posterior probability of OR > 1 [P(OR > 1)] 1] = 0.004; and OR = 0.86, 95% CrI 0.76-0.98, P[OR > 1] = 0.015, respectively). The results minimally changed, even in various sensitivity and covariate-adjusted meta-regression analyses. ICS/LAMA/LABA tended to lower the risk of cardiovascular mortality but did not show significant results. ICS/LAMA/LABA increased the probability of pneumonia (OR for triple therapy = 1.56; 95% CrI 1.19-2.03; P[OR > 1] = 1.000). The main limitation is that there were few RCTs including only less symptomatic patients or patients at a low risk. Conclusions These findings suggest that triple therapy can potentially be the best option for stable COPD patients in terms of reducing exacerbation and all-cause mortality.

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results